Maxigen Biotech Inc
TWSE:1783
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Maxigen Biotech Inc
Free Cash Flow
Maxigen Biotech Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Maxigen Biotech Inc
TWSE:1783
|
Free Cash Flow
NT$223m
|
CAGR 3-Years
0%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grape King Bio Ltd
TWSE:1707
|
Free Cash Flow
NT$1.7B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Maywufa Co Ltd
TWSE:1731
|
Free Cash Flow
NT$203.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
13%
|
CAGR 10-Years
3%
|
|
|
Chlitina Holding Ltd
TWSE:4137
|
Free Cash Flow
NT$555.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
1%
|
|
Maxigen Biotech Inc
Glance View
Maxigen Biotech, Inc. engages in the research, development, manufacturing, and sales of biomedical materials and beauty care products. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2011-05-18. The firm operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.
See Also
What is Maxigen Biotech Inc's Free Cash Flow?
Free Cash Flow
223m
TWD
Based on the financial report for Sep 30, 2025, Maxigen Biotech Inc's Free Cash Flow amounts to 223m TWD.
What is Maxigen Biotech Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
38%
Over the last year, the Free Cash Flow growth was -10%.
